Daily practice study of rituximab for pemphigus: a retrospective study of 65 patients.


dr. B. Horvath
H. Rashid

Nature of the research:
retrospective database study

Fields of study:

Background / introduction
Pemphigus is a group of mucocutaneous blistering diseases mediated by autoantibodies against the desmosomal cadherines of the epidermis. Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the two major forms of this chronic autoimmune disease. Multiple therapeutic strategies are available for pemphigus vulgaris and pemphigus foliaceus. Long-term high doses of systemic corticosteroids are considered the mainstay treatment of this group of diseases which are associated with significant adverse effects. Recent studies showed high effectiveness of rituximab (RTX), an anti-CD20 antibody, in pemphigus.
Research question / problem definition
To assess the effectiveness of RTX in pemphigus patients.
Retrospective single-center patient chart study between 2012 and 2017. All patients with pemphigus treated with RTX are included in the study. From each subject data regarding clinical and diagnostic findings, treatment responses and follow-up are already partially collected. Data concerning relapses and immunological test results still need to be collected.
back to toptop

Laatst gewijzigd: 23 februari 2012